Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
2012; Massachusetts Medical Society; Volume: 368; Issue: 2 Linguagem: Inglês
10.1056/nejmoa1209096
ISSN1533-4406
AutoresCharles J. Ryan, Matthew R. Smith, Johann S. de Bono, Arturo Molina, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Paul N. Mainwaring, Josep M. Piulats, Siobhan Ng, Joan Carles, Peter F.A. Mulders, Ethan Basch, Eric J. Small, Fred Saad, Dirk Schrijvers, Hendrik Van Poppel, Som D. Mukherjee, H. Suttmann, Winald R. Gerritsen, Thomas W. Flaig, Daniel J. George, Evan Y. Yu, Eleni Efstathiou, Allan J. Pantuck, Eric Winquist, Celestia S. Higano, Mary-Ellen Taplin, Youn Park, Thian Kheoh, Thomas W. Griffin, Howard I. Scher, Dana E. Rathkopf,
Tópico(s)Hormonal and reproductive studies
ResumoAbiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy.
Referência(s)